selected scholarly activity
-
chapters
- Cannabis and Anxiety. 107-119. 2023
- 18 Apps for mental health. 395-433. 2022
- Apps for mental health. 395-433. 2022
- Recognizing Posttraumatic Stress Disorder in Primary Care. 131-156. 2021
- The Epidemiology of PTSD in Canada. 157-173. 2021
- Use of Digital Technology and Mobile Applications to Treat Anxiety Disorders. 387-397. 2020
- Pharmacotherapy for Adolescent Social Phobia. 301-322. 2015
- Serotonin reuptake and receptor blockers. 26-47. 2012
- Commentaries. 163-170. 2011
- Commentaries. 163-170. 2011
- Pharmacotherapy for Generalized Anxiety Disorder. 193-218. 2009
- Pharmacotherapy for Social Anxiety Disorder and Specific Phobia 2008
- Antiepileptic drugs in the treatment of anxiety disorders: Role in therapy. 207-249. 2008
- Epidemiology of Phobias: The Pathway to Early Intervention in Anxiety Disorders. 113-115. 2005
-
conferences
- A 14-Week, Randomized, Placebo-Controlled Cross-Over Study of Multilayer Release Methylphenidate in Adult ADHD With and Without Anxiety Disorder Comorbidity. Neuropsychopharmacology. 309-310. 2023
- An update on the Pharmacological and Psychotherapeutic Management of Treatment Resistant OCD. European psychiatry. S26-S27. 2023
- Correlates and Patterns of Cannabis Use in an ADHD Sample. Neuropsychopharmacology. 176-177. 2022
- Correlates and Patterns of Cannabis Use in an ADHD Sample. Neuropsychopharmacology. 176-177. 2022
- Obsessive Compulsive Disorder During the COVID-19 Pandemic. Neuropsychopharmacology. 310-311. 2021
- P.0266 The mental health response to the first wave of covid-19 in an international sample. European Neuropsychopharmacology. S192-S192. 2021
- A Pilot Survey of Cannabis Use in Individuals With Obsessive Compulsive Disorder. Neuropsychopharmacology. 330-330. 2019
- P.492 Selective sound sensitivity (misophonia): characteristics of an online sample. European Neuropsychopharmacology. S346-S346. 2019
- E.01.01 Pharmacological treatment of resistant OCD. European Neuropsychopharmacology. S32-S32. 2019
- Lisdexamfetamine dimesylate in adult ADHD with anxiety disorder and depression comorbidity: A 17-week cross-over study. European Neuropsychopharmacology. S433-S433. 2019
- Anxiety and Depressive Symptom Prevalence in a Canadian Medical Cannabis Use Cohort. Neuropsychopharmacology. S389-S390. 2018
- Genetic Variants of OCD Phenotypes and Comorbid Conditions. Neuropsychopharmacology. S156-S157. 2018
- EXPLORING SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF OLDER ADULTS WITH OBSESSIVE-COMPULSIVE DISORDER: A REPORT FROM THE INTERNATIONAL COLLEGE OF OBSESSIVE-COMPULSIVE DISORDERS (ICOCS). European Neuropsychopharmacology. 765-766. 2018
- HOARDING IN USERS OF ONLINE CLASSIFIED ADVERTSEMENTS. European Neuropsychopharmacology. 763-763. 2018
- INTERNET ADDICTION OR PSYCHOPATHOLOGY IN DISGUISE? RESULTS FROM A SURVEY OF COLLEGE-AGED INTERNET USERS. European Neuropsychopharmacology. 762-762. 2018
- EFFICACY AND SAFETY OF AGOMELATINE (25-50 MG/DAY) VERSUS ESCITALOPRAM (10-20 MG/DAY) IN SEVERE GENERALIZED ANXIETY DISORDER. Australian and New Zealand Journal of Psychiatry. 136-137. 2018
- Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder and Depression Comorbidity: Results From a Clinical Trial. Neuropsychopharmacology. S342-S343. 2017
- Pokémon Go: is it a potential tool for mental health?. European Neuropsychopharmacology. S1125-S1125. 2017
- Prevalence of anxiety and depressive symptoms in a Canadian medical cannabis use cohort. European Neuropsychopharmacology. S1002-S1003. 2017
- CHILDHOOD, ADOLESCENT AND ADULT AGE AT ONSET AND RELATED CLINICAL CORRELATES IN OBSESSIVE-COMPULSIVE DISORDER: A REPORT FROM THE INTERNATIONAL COLLEGE OF OBSESSIVE-COMPULSIVE DISORDERS (ICOCS). European Neuropsychopharmacology. 610-611. 2017
- Adult ADHD With Anxiety Disorder and Depression Comorbidity in a Clinical Trial Cohort. Neuropsychopharmacology. S486-S487. 2016
- Hoarding in users of online classified advertisements. European Neuropsychopharmacology. S622-S623. 2016
- Internet addiction or psychopathology in disguise? Results from a survey of college-aged internet users. European Neuropsychopharmacology. S700-S701. 2016
- Hoarding Behaviours among Users of Online Classified Advertisements. Neuropsychopharmacology. S457-S458. 2015
- P.6.e.002 Problematic internet use in the general population: results from an internet-based survey. European Neuropsychopharmacology. S627-S627. 2015
- The Use of Augmentation Strategies in Treatment Resistant Anxiety Disorders: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. S350-S351. 2014
- P.4.a.007 Internet use for social communication in adolescents with social anxiety disorder. European Neuropsychopharmacology. S580-S580. 2014
- P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review. European Neuropsychopharmacology. S605-S606. 2014
- Augmentation strategies in treatment resistant anxiety disorders: Meta-analysis and systematic review. International Journal of Neuropsychopharmacology. 130-130. 2014
- Technology-based communication in individuals with social phobia. International Journal of Neuropsychopharmacology. 130-131. 2014
- Perceptions of Obsessive Compulsive Disorder and Potential Impact on Treatment Outcome. Neuropsychopharmacology. S529-S530. 2013
- P.4.e.007 Perceptions of obsessive compulsive disorder and the impact on treatment outcomes. European Neuropsychopharmacology. S528-S528. 2013
- P.4.e.008 The use of technology-based communication and the impact on the social functioning of individuals with and without social phobia. European Neuropsychopharmacology. S529-S529. 2013
- A Case Series of N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorders. Journal of Obsessive-Compulsive and Related Disorders. 230-231. 2013
- P.4.a.010 Adult attention deficit hyperactivity disorder and anxiety disorder comorbidity: prevalence in a clinical sample. European Neuropsychopharmacology. S362-S363. 2012
- P.4.e.007 Internet screening for anxiety disorders and effects on treatment-seeking three months later. European Neuropsychopharmacology. S376-S377. 2012
- Internet screening for anxiety disorders : Effects on treatment-seeking behaviour in a 3-month follow-up study. International Journal of Neuropsychopharmacology. 95-95. 2012
- Prevalence of adult attention deficit hyperactivity disorder in anxiety disorders sample. International Journal of Neuropsychopharmacology. 223-224. 2012
- P.4.b.005 Panic attacks and generalised anxiety disorder. European Neuropsychopharmacology. S534-S535. 2011
- P.4.b.019 Panic attacks associated with generalised anxiety disorder. European Neuropsychopharmacology. S540-S540. 2010
- P.4.a.006 Internet-based screening of anxiety disorders. European Neuropsychopharmacology. S588-S589. 2009
- P.4.f.001 The impact of changing diagnostic criteria in posttraumatic stress disorder (PTSD). European Neuropsychopharmacology. S618-S619. 2009
- Influence of gender on the clinical presentation of generalized anxiety disorder, and response to treatment with Pregabalin. European psychiatry. S221-S222. 2008
- P.4.a.008 A randomized placebo controlled trial of olanzapine in trichotillomania. European Neuropsychopharmacology. S452-S452. 2006
- Paroxetine-induced increase in LDL cholesterol levels. Neuropsychopharmacology. S177-S177. 2005
- A pilot study of topiramate augmentation in treatment resistant obsessive-compulsive disorder. European Neuropsychopharmacology. S553-S554. 2005
- Tiagabine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. European Neuropsychopharmacology. S538-S538. 2005
- Tiagabine in patients with generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. Neuropsychopharmacology. S213-S214. 2004
- P.3.008 Treatment of trichotillomania with atypicalantipsychotics: A case series. European Neuropsychopharmacology. S306-S307. 2004
- A randomized, double-blind, placebo-controlled trial of tiagabine in the treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology. S366-S366. 2004
- Topiramate augmentation in a case series of treatment resistant obsessive compulsive disorder. International Journal of Neuropsychopharmacology. S368-S368. 2004
- Topiramate in generalized social phobia: An open trial. International Journal of Neuropsychopharmacology. S371-S371. 2004
- Trichotillomania: Effective treatment with quetiapine. A case series. International Journal of Neuropsychopharmacology. S367-S367. 2004
- WCA recommendations for the long-term treatment of social phobia. CNS Spectrums. 40-52. 2003
- Predictors of remission in patients treated with sertraline for moderate to severe generalized social phobia. European Neuropsychopharmacology. S342-S342. 2002
- P02.231 24-week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatment. European psychiatry. 384s-384s. 2000
- P02.231 24-week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatment. European psychiatry. s384-s384. 2000
- 101. A pilot study of PET in social phobia. Biological Psychiatry. S31-S31. 1998
-
journal articles
- An update from the WPA Section on Anxiety and Obsessive-Compulsive Disorders.. World Psychiatry. 23:456-457. 2024
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Canadian Journal of Psychiatry. 69:641-687. 2024
- Lessons from a multicenter, international, large sample size analysis of patients with obsessive–compulsive disorders: an overview of the ICOCS Snapshot studies. CNS Spectrums. 29:40-48. 2024
- The definition of treatment resistance in anxiety disorders: a Delphi method‐based consensus guideline. World Psychiatry. 23:113-123. 2024
- North American open-label 16-week trial of the MindShift smartphone app for adult anxiety. Journal of Mood & Anxiety Disorders. 4:100036-100036. 2023
- Changes in posttraumatic stress disorder symptom severity during the COVID-19 pandemic: Ten-wave findings from a longitudinal observational cohort study of community adults. Psychiatry Research. 329:115496-115496. 2023
- Who really hoards? Hoarding symptoms in adults with attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD) and healthy controls. Journal of Psychiatric Research. 166:74-79. 2023
- Cannabis use and related clinical variables in patients with obsessive-compulsive disorder. CNS Spectrums. 28:505-513. 2023
- Periodicity and severity of changes in depression and anxiety during the COVID-19 pandemic: Ten-wave longitudinal findings from an observational cohort study of community adults. Psychiatry Research. 326:115267-115267. 2023
- Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder. Alcohol and alcoholism (Oxford, Oxfordshire). Supplement. 58:337-345. 2023
- Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry. 68:299-311. 2023
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. World Journal of Biological Psychiatry. 24:79-117. 2023
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. World Journal of Biological Psychiatry. 24:118-134. 2023
- Cannabis use in Attention – Deficit/Hyperactivity Disorder (ADHD): A scoping review. Journal of Psychiatric Research. 157:239-256. 2023
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Canadian Journal of Psychiatry. 68:5-21. 2023
- Treatment-resistant OCD: Pharmacotherapies in adults. Comprehensive Psychiatry. 120:152352-152352. 2023
- Understanding video streaming: characteristics of a large internet sample. Neuroscience Applied. 2:102762-102762. 2023
- Problematic video-streaming: a short review. Current Opinion in Behavioral Sciences. 48:101232-101232. 2022
- Advances in problematic usage of the internet research – A narrative review by experts from the European network for problematic usage of the internet. Comprehensive Psychiatry. 118:152346-152346. 2022
- Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review. Asian Journal of Psychiatry. 76:103232-103232. 2022
- Attitudes and Beliefs Toward Cannabis Before Recreational Legalization: A Cross-Sectional Study of Community Adults in Ontario. Cannabis and Cannabinoid Research. 7:526-536. 2022
- The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. Comprehensive Psychiatry. 116:152315-152315. 2022
- Characterizing problematic internet use in a sample of heavy drinking emerging adults.. Psychology of Addictive Behaviors. 36:307-317. 2022
- Mental health during the first wave of COVID-19 in Canada, the USA, Brazil and Italy. International Journal of Psychiatry in Clinical Practice. 26:148-156. 2022
- Obsessive-compulsive disorder during the COVID-19 pandemic. Journal of Psychiatric Research. 149:114-123. 2022
- Functional interventions as augmentation strategies for obsessive-compulsive disorder (OCD): scoping review and expert survey from the international college of obsessive-compulsive spectrum disorders (ICOCS). International Journal of Psychiatry in Clinical Practice. 26:92-107. 2022
- Long-term functional impairment and the impact of hospitalization for covid-19. Neuroscience Applied. 1:100735-100735. 2022
- Cannabis use and misuse in the year following recreational cannabis legalization in Canada: A longitudinal observational cohort study of community adults in Ontario. Drug and Alcohol Dependence. 225:108781-108781. 2021
- Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. Journal of Psychiatric Research. 140:357-363. 2021
- Daily, but not occasional, cannabis use is selectively associated with more impulsive delay discounting and hyperactive ADHD symptoms in binge-drinking young adults. Psychopharmacology. 238:1753-1763. 2021
- Anxiety, depression and stress during the COVID-19 pandemic: Results from a cross-sectional survey. Journal of Psychiatric Research. 137:96-103. 2021
- Binge eating disorder hidden behind a wall of anxiety disorders. Journal of Psychiatry & Neuroscience. 46:E208-E209. 2021
- Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. International Clinical Psychopharmacology. 36:61-75. 2021
- Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies. Advances in Therapy. 38:1567-1583. 2021
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Canadian Journal of Psychiatry. 66:113-125. 2021
- Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. Comprehensive Psychiatry. 102:152188-152188. 2020
- The gut microbiome and inflammation in obsessive‐compulsive disorder patients compared to age‐ and sex‐matched controls: a pilot study. Acta Psychiatrica Scandinavica. 142:337-347. 2020
- Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. International Clinical Psychopharmacology. 35:173-193. 2020
- How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Comprehensive Psychiatry. 100:152174-152174. 2020
- Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). CNS Spectrums. 25:419-425. 2020
- Early detection and intervention for obsessive-compulsive disorder in childhood and adolescence. The Lancet Child and Adolescent Health. 4:99-101. 2020
- Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cognitive Behaviour Therapy. 49:1-21. 2020
- The role of cannabis in treating anxiety. Current Opinion in Psychiatry. 33:1-7. 2020
- Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder. Journal of Psychiatric Research. 118:1-6. 2019
- The gut microbiome in psychiatry: A primer for clinicians. Depression and Anxiety. 36:1004-1025. 2019
- Biological and psychosocial predictors of anxiety worsening in the postpartum period: A longitudinal study. Journal of Affective Disorders. 250:218-225. 2019
- Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. Journal of Psychiatric Research. 111:134-139. 2019
- Early intervention for obsessive compulsive disorder: An expert consensus statement. European Neuropsychopharmacology. 29:549-565. 2019
- Neuroimaging findings as predictors of treatment outcome of psychotherapy in anxiety disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 91:60-71. 2019
- Prevalence of hoarding behaviours and excessive acquisition in users of online classified advertisements. Psychiatry Research. 270:194-197. 2018
- Manifesto for a European research network into Problematic Usage of the Internet. European Neuropsychopharmacology. 28:1232-1246. 2018
- 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder. European Neuropsychopharmacology. 28:970-979. 2018
- Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectrums. 23:59-66. 2018
- The Treatment of Refractory Generalized Anxiety Disorder. Current Treatment Options in Psychiatry. 4:404-417. 2017
- An Update on the Relationship Between the Gut Microbiome and Obsessive-Compulsive Disorder. Psychiatric Annals. 47:542-551. 2017
- Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?. Depression and Anxiety. 34:1006-1017. 2017
- Placebo response in trichotillomania. International Clinical Psychopharmacology. 32:350-355. 2017
- Obsessive-compulsive disorder in the elderly: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). European psychiatry. 45:36-40. 2017
- There is an app for that! The current state of mobile applications (apps) for DSM-5 obsessive-compulsive disorder, posttraumatic stress disorder, anxiety and mood disorders. Depression and Anxiety. 34:526-539. 2017
- Augmentation Strategies for Treatment-Resistant Anxiety Disorders: A Systematic Review and Meta-Analysis. Focus: The Journal of Lifelong Learning in Psychiatry. 15:219-226. 2017
- Refractory social anxiety disorder. Journal of Psychiatry & Neuroscience. 42:E1-E2. 2017
- The use of waitlists as control conditions in anxiety disorders research. Journal of Psychiatric Research. 83:112-120. 2016
- Childhood, adolescent and adult age at onset and related clinical correlates in obsessive–compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice. 20:210-217. 2016
- AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Depression and Anxiety. 33:728-736. 2016
- Standards of care for obsessive–compulsive disorder centres. International Journal of Psychiatry in Clinical Practice. 20:204-208. 2016
- New treatment models for compulsive disorders. European Neuropsychopharmacology. 26:877-884. 2016
- “WHAT'S BUGGING THE GUT IN OCD?” A REVIEW OF THE GUT MICROBIOME IN OBSESSIVE-COMPULSIVE DISORDER. Depression and Anxiety. 33:171-178. 2016
- In the wake of a possible mistake: Security motivation, checking behavior, and OCD. Journal of Behavior Therapy and Experimental Psychiatry. 49:133-140. 2015
- Internet screening for anxiety disorders: Treatment-seeking outcomes in a three-month follow-up study. Psychiatry Research. 230:689-694. 2015
- Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectrums. 20:469-473. 2015
- Topiramate augmentation in a patient with obsessive–compulsive disorder. Journal of Psychiatry & Neuroscience. 40:E31-E32. 2015
- Increased activity of frontal and limbic regions to emotional stimuli in children at-risk for anxiety disorders. Psychiatry Research. 233:9-17. 2015
- Frontal EEG alpha activity and obsessive-compulsive behaviors in non-clinical young adults: a pilot study. Frontiers in Psychology. 6:1480. 2015
- The Human Ortholog of Acid-Sensing Ion Channel Gene ASIC1a Is Associated With Panic Disorder and Amygdala Structure and Function. Biological Psychiatry. 76:902-910. 2014
- Comorbidity in obsessive–compulsive disorder (OCD): A report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). Comprehensive Psychiatry. 55:1513-1519. 2014
- Response to Silberman. American Journal of Psychiatry. 171:795-796. 2014
- DSM-5 OBSESSIVE-COMPULSIVE AND RELATED DISORDERS: CLINICAL IMPLICATIONS OF NEW CRITERIA. Depression and Anxiety. 31:487-493. 2014
- Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. Journal of Psychopharmacology. 28:596-602. 2014
- Influence of RGS2 on Sertraline Treatment for Social Anxiety Disorder. Neuropsychopharmacology. 39:1340-1346. 2014
- A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety Disorder. American Journal of Psychiatry. 171:44-53. 2014
- Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 14:S1-S1. 2014
- Development of a Brief Version of the Social Phobia Inventory Using Item Response Theory: The Mini-SPIN-R. Behavior Therapy. 44:651-661. 2013
- The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology. 23:865-871. 2013
- N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. Journal of Obsessive-Compulsive and Related Disorders. 2:48-52. 2013
- Panic Attacks in Generalized Anxiety Disorder. Journal of Nervous and Mental Disease. 201:52-55. 2013
- Avoidant personality disorder in individuals with generalized social anxiety disorder: What does it add?. Journal of Anxiety Disorders. 26:665-672. 2012
- Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive–compulsive disorder. International Clinical Psychopharmacology. 27:1-1. 2012
- Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 16:77-84. 2012
- When Too Much Is Not Enough: Obsessive-Compulsive Disorder as a Pathology of Stopping, Rather than Starting. PLoS ONE. 7:e30586-e30586. 2012
- The Impact of Changing Diagnostic Criteria in Posttraumatic Stress Disorder in a Canadian Epidemiologic Sample. Journal of Clinical Psychiatry. 72:1034-1041. 2011
- Adult Attention Deficit Hyperactivity Disorder in an Anxiety Disorders Population. CNS Neuroscience and Therapeutics. 17:221-226. 2011
- Frontal Brain Oscillatory Coupling in Children of Parents With Social Phobia: A Pilot Study. Journal of Neuropsychiatry and Clinical Neurosciences. 23:111-114. 2011
- The Burden of Anxiety Disorders on the Family. Journal of Nervous and Mental Disease. 198:876-880. 2010
- Book Review: Anxiety Disorders: The Anti-Anxiety Workbook. Canadian Journal of Psychiatry. 55:744-745. 2010
- Potential use of Internet-based screening for anxiety disorders: a pilot study. Depression and Anxiety. 27:1006-1010. 2010
- A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania. Journal of Clinical Psychiatry. 71:1336-1343. 2010
- A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder. Current Psychiatry Reports. 12:471-477. 2010
- The psychology of potential threat: Properties of the security motivation system. Biological Psychology. 85:331-337. 2010
- The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample. CNS Neuroscience and Therapeutics. 16:76-82. 2010
- Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. Depression and Anxiety. 26:1027-1032. 2009
- Paroxetine-induced increase in LDL cholesterol levels. Journal of Psychopharmacology. 23:826-830. 2009
- Trichotillomania in youth: a retrospective case series. Depression and Anxiety. 26:661-665. 2009
- Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. International Clinical Psychopharmacology. 24:87-96. 2009
- Pharmacotherapy for social anxiety disorder: an update.. Israel Journal of Psychiatry and Related Sciences. 46:53-61. 2009
- Post‐Traumatic Stress Disorder in Canada. CNS Neuroscience and Therapeutics. 14:171-181. 2008
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. World Journal of Biological Psychiatry. 9:248-312. 2008
- Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. Journal of Psychopharmacology. 21:472-476. 2007
- Nefazodone in the Treatment of Generalized Social Phobia. Journal of Clinical Psychiatry. 68:288-295. 2007
- BEHAVIORAL AND PSYCHOPHYSIOLOGICAL CHARACTERISTICS OF CHILDREN OF PARENTS WITH SOCIAL PHOBIA: A PILOT STUDY. International Journal of Neuroscience. 117:605-616. 2007
- Topiramate augmentation in treatment-resistant obsessive–compulsive disorder: a retrospective, open-label case series. Depression and Anxiety. 23:1-5. 2006
- Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 5:44. 2005
- Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 5:5. 2005
- The Selective GABA Reuptake Inhibitor Tiagabine for the Treatment of Generalized Anxiety Disorder. Journal of Clinical Psychiatry. 66:1401-1408. 2005
- Emerging Treatments for Child and Adolescent Social Phobia: AReview. Journal of Child and Adolescent Psychopharmacology. 15:589-607. 2005
- An evaluation of paroxetine in generalised social anxiety disorder. Expert Opinion on Pharmacotherapy. 6:819-830. 2005
- Individuals with social phobia are biased to become aware of negative faces. Visual Cognition. 12:159-179. 2005
- An Open Trial of Topiramate in the Treatment of Generalized Social Phobia. Journal of Clinical Psychiatry. 65:1674-1678. 2004
- A PET provocation study of generalized social phobia. Psychiatry Research. 132:13-18. 2004
- Optimizing Treatment in Social Phobia: A Review of Treatment Resistance. CNS Spectrums. 9:753-762. 2004
- Book Review: Anxiety Disorders: Cognitive-Behavioral Group Therapy for Social Phobia: Basic Mechanisms and Clinical Strategies. Canadian Journal of Psychiatry. 49:149-150. 2004
- Predictors of Response in Generalized Social Phobia. Journal of Clinical Psychopharmacology. 24:42-48. 2004
- Antiepileptic Drugs in the Treatment of Anxiety Disorders. Drugs. 64:2199-2220. 2004
- WCA Recommendations for the Long-Term Treatment of Social Phobia. CNS Spectrums. 8:40-52. 2003
- A confirmatory factor analysis of a self‐report version of the Liebowitz Social Anxiety Scale. Journal of Clinical Psychology. 59:149-161. 2003
- Quality of life and the anxiety disorders. Journal of Anxiety Disorders. 17:405-426. 2003
- The impact of anxiety disorders on educational achievement. Journal of Anxiety Disorders. 17:561-571. 2003
- Topiramate Treatment for SSRI-Induced Weight Gain in Anxiety Disorders. Journal of Clinical Psychiatry. 63:981-984. 2002
- Sertraline and Fluoxetine Treatment of Obsessive-Compulsive Disorder: Results of a Double-Blind, 6-Month Treatment Study. Journal of Clinical Psychopharmacology. 22:148-154. 2002
- Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive–compulsive disorder?. Journal of Affective Disorders. 68:59-65. 2002
- PHARMACOTHERAPY OF SOCIAL ANXIETY DISORDER AT THE TURN OF THE MILLENNIUM. Psychiatric Clinics of North America. 24:783-803. 2001
- Pharmacotherapy of social anxiety disorder: an algorithm for primary care 2001. Primary Care and Community Psychiatry. 7:107-110. 2001
- Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry. 158:275-281. 2001
- Predictors of sertraline response in the treatment of generalized social phobia. European Neuropsychopharmacology. 11:S304-S304. 2001
- Prevention of Relapse in Generalized Social Phobia: Results of a 24-Week Study in Responders to 20 Weeks of Sertraline Treatment. Journal of Clinical Psychopharmacology. 20:636-644. 2000
- Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opinion on Investigational Drugs. 9:2215-2231. 2000
- 24-Week prevention of relapse of generalized social phobia study in responders to 20-weeks of sertraline treatment. European Neuropsychopharmacology. 10:336-336. 2000
- A placebo-controlled study of sertraline in generalized social phobia. European Neuropsychopharmacology. 10:335-335. 2000
- The neurobiology of social phobia: From pharmacotherapy to brain imaging. Current Psychiatry Reports. 2:358-366. 2000
- Book Review: The Anxiety Disorders. Canadian Journal of Psychiatry. 45:293-294. 2000
- The potential role of haloperidol in the treatment of trichotillomania. Journal of Affective Disorders. 56:219-226. 1999
- Pharmacotherapy for Social Phobia: What Works, What Might Work, and What Does Not Work at All. CNS Spectrums. 4:61-68. 1999
- Childhood attention deficit/hyperactivity disorder in adults with anxiety disorders. Psychological Medicine. 29:515-525. 1999
- Nefazodone in Social Phobia. Journal of Clinical Psychiatry. 60:96-100. 1999
- Selective Serotonin Reuptake Inhibitors in the Treatment of Social Phobia. CNS Drugs. 11:307-315. 1999
- Serotonergic agents in the treatment of social phobia in children and adolescents: A case series. Depression and Anxiety. 10:33-39. 1999
- Nefazodone in social phobia: A pilot study. European Neuropsychopharmacology. 8:S266-S266. 1998
- The Relationship of Behavioral Inhibition and Shyness to Anxiety Disorder. Journal of Nervous and Mental Disease. 186:425-431. 1998
- An open trial of nefazodone in the treatment of social phobia. Biological Psychiatry. 42:27S-27S. 1997
- Haloperidol treatment of trichotillomania: A pilot study. Biological Psychiatry. 42:26S-26S. 1997
- Paroxetine in Social Phobia. Journal of Clinical Psychiatry. 57:519-522. 1996
- A High-Risk Pilot Study of the Children of Adults with Social Phobia. Journal of the American Academy of Child and Adolescent Psychiatry. 35:1511-1517. 1996
- Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder. The British journal of psychiatry. Supplement. 169:468-474. 1996
- Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. Journal of Affective Disorders. 39:115-121. 1996
- Relationship of Childhood Sexual and Physical Abuse to Anxiety Disorders. Journal of Nervous and Mental Disease. 183:309-314. 1995
- Sertraline in social phobia. Journal of Affective Disorders. 31:141-145. 1994
- Fluoxetine efficacy in social phobia.. Journal of Clinical Psychiatry. 54:27-32. 1993
- Adverse Effects of Switching from Fluoxetine to Desipramine. Canadian Journal of Psychiatry. 37:278-278. 1992
- Relationship of social phobia with other psychiatric illness. Journal of Affective Disorders. 21:93-99. 1991